X-SCID Gene Therapy Risks Not Generalizable To Other Conditions, Cmte. Says
This article was originally published in The Pink Sheet Daily
FDA's Cellular, Tissue & Gene Therapies Advisory Committee points to unique factors in the biological basis of X-linked severe combined immunodeficiency disorder and the fact that leukemia cases have been seen in only one study.
You may also be interested in...
The Solicitor General says the Supreme Court should not hear the Commission's appeal of a case brought against Schering-Plough regarding a generic drug settlement.
Fox Chase Cancer Center’s Weeks concurs that umbrella agreements with pharma and biotech companies are becoming more common.
Tests are currently available to identify patient responders, but clinicians need guidance on how to adjust dosing for them, the HHS Secretary's Advisory Committee on Genetics, Health & Society agreed.